Does APIXABAN Cause Interstitial lung disease? 559 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 559 reports of Interstitial lung disease have been filed in association with APIXABAN (ELIQUIS). This represents 0.4% of all adverse event reports for APIXABAN.
559
Reports of Interstitial lung disease with APIXABAN
0.4%
of all APIXABAN reports
97
Deaths
303
Hospitalizations
How Dangerous Is Interstitial lung disease From APIXABAN?
Of the 559 reports, 97 (17.4%) resulted in death, 303 (54.2%) required hospitalization, and 95 (17.0%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for APIXABAN. However, 559 reports have been filed with the FAERS database.
What Other Side Effects Does APIXABAN Cause?
Death (18,501)
Cerebrovascular accident (7,237)
Atrial fibrillation (5,690)
Off label use (5,590)
Thrombosis (5,298)
Fall (5,063)
Cardiac disorder (4,917)
Haemorrhage (4,770)
Dyspnoea (4,379)
Gastrointestinal haemorrhage (4,030)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which APIXABAN Alternatives Have Lower Interstitial lung disease Risk?
APIXABAN vs APOMORPHINE
APIXABAN vs APRACLONIDINE
APIXABAN vs APREMILAST
APIXABAN vs APREPITANT
APIXABAN vs APROTININ